2021 Year in Review - HER2-Negative Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
Clinical studies have demonstrated that olaparib is clinically efficacious in patients with germline BRCA mutation–positive, HER2-negative metastatic breast cancer in a setting closely resembling the real world.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline BRCA mutation–positive metastatic breast cancer than in patients with germline BRCA wild-type disease and unclear germline BRCA status, implying possible changes in tumor biology.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
PARP inhibitors offer the possibility of biomarker-targeted treatment for breast cancer. Therefore, it is necessary to quickly identify which patients may benefit from treatment and to guarantee that genetic testing is available.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive, HER2-negative, advanced breast cancer.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
In a real-world study, more than 60% of the HR-positive, HER2-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.
2021 Year in Review - HER2-Negative Breast Cancer | January 21, 2022
The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512